EYPT NASDAQ
EyePoint Pharmaceuticals, Inc.
1W: -3.5%
1M: -10.2%
3M: -16.6%
YTD: -26.9%
1Y: +105.8%
3Y: +115.2%
5Y: +44.1%
$12.93
+0.15 (+1.17%)
Weekly Expected Move ±6.4%
$11
$12
$12
$13
$14
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.00
Neutral
0 bullish
1 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (43)
EyePoint Announces Participation at Upcoming Investor Conferences
EyePoint Announces Third Consecutive Positive DSMC Recommendation for Phase 3 Wet AMD Trials for DURAVYU™, Building Confidence Ahead of Mid-2026 Topline Data
EyePoint (EYPT) Q1 2026 Earnings Transcript
EyePoint targets wet AMD Phase III top line data mid-year while projecting cash runway into Q4 2027
Earnings Scheduled For May 6, 2026
EyePoint (EYPT) Reports Q1 Loss, Tops Revenue Estimates
EyePoint Pharmaceuticals GAAP EPS of -$0.99 misses by $0.19, revenue of $0.7M beats by $0.35M
EyePoint Reports First Quarter 2026 Financial Results and Highlights Recent Corporate Developments
EyePoint Pharmaceuticals Q1 2026 Earnings Preview
EyePoint to Report First Quarter 2026 Financial Results on May 6, 2026
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Insider Ramiro Ribeiro Sells 2,437 Shares of Stock
Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Consensus Recommendation of “Buy” by Brokerages
Aberdeen Group plc Has $29.34 Million Position in Eyepoint Pharmaceuticals, Inc. $EYPT
Arvinas (ARVN) Moves 6.9% Higher: Will This Strength Last?
Arvinas (ARVN) Moves 6.9% Higher: Will This Strength Last?
EyePoint sues Ocular over claims related to lead asset
Revolution, Ascendis, Arrowhead among RBC’s top M&A candidates in biotech
This Biotech Stock Up Nearly 100% in a Year Has Drawn a New $20 Million Share Investment
Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Average Recommendation of “Buy” by Analysts
What is HC Wainwright’s Estimate for EYPT Q1 Earnings?
EyePoint outlines mid-2026 topline data target for DURAVYU in wet AMD and DME as Phase III trials advance
EyePoint (EYPT) Q4 2025 Earnings Call Transcript
EyePoint (EYPT) Reports Q4 Loss, Tops Revenue Estimates
EyePoint Pharmaceuticals GAAP EPS of -$0.81 misses by $0.08, revenue of $0.62M misses by $0.39M
Earnings Summary: EyePoint Q4
EyePoint Reports Fourth Quarter and Full-Year 2025 Financial Results and Highlights Recent Corporate Developments
EyePoint Reports Fourth Quarter and Full-Year 2025 Financial Results and Highlights Recent Corporate Developments
Earnings Scheduled For March 4, 2026
Here are the major earnings before the open Wednesday
A Preview Of EyePoint Pharmaceuticals's Earnings
EyePoint Pharmaceuticals Q4 2025 Earnings Preview
EyePoint Announces First Patients Dosed in Both Global Phase 3 Clinical Trials of DURAVYU™ for the Treatment of Diabetic Macular Edema
EyePoint to Report Fourth Quarter and Full-Year 2025 Financial Results on March 4, 2026
EyePoint Announces Participation at Upcoming Investor Conferences
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Wall Street Thinks These 4 Biotech Stocks Will Double–At Least–This Year
EyePoint to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
EyePoint, Inc. (EYPT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
EyePoint (EYPT) Is Up 9.01% in One Week: What You Should Know
EyePoint to Present at the 44th Annual J.P. Morgan Healthcare Conference
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
EyePoint Announces Positive Recommendation from Independent Data Safety Monitoring Committee for Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Related Macular Degeneration